Literature DB >> 23379765

PTEN modulators: a patent review.

Chandra S Boosani1, Devendra K Agrawal.   

Abstract

INTRODUCTION: PTEN (phosphatase and tensin homolog deleted on chromosome 10) plays a pivotal role in controlling intracellular signaling for cell survival and proliferation by inhibiting the PI3K/Akt pathway, and its dysfunction is associated with several neoplastic diseases. PTEN is frequently found mutated in many pathological conditions highlighting its importance in normal physiological function. Unlike several cellular proteins which are activated by phosphorylation, PTEN is inactivated upon phosphorylation by specific kinases which phosphorylate serine and threonine residues in its C-terminal region. Therefore, development of therapeutic agents that specifically target kinases and kinase-domain-containing proteins affecting PTEN would lead to the treatment of PTEN-related diseases. AREAS COVERED: With increasing evidence on the role of PTEN in many human diseases, the present review focuses on the clinical relevance of PTEN with a comprehensive list of currently identified modulators of PTEN, and proposes potentially novel molecular targets which could aid in the development of drug candidates for the treatment of PTEN-related diseases such as cardiovascular diseases, diabetes, obesity, cancer, autism, Parkinson's and Alzheimer's diseases. EXPERT OPINION: This review describes several target sites that could help in the development of novel drug candidates to regulate or restore the normal physiological functions of PTEN and are essential in the treatment of human diseases where PTEN plays a pivotal role.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23379765      PMCID: PMC3653164          DOI: 10.1517/13543776.2013.768985

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  81 in total

1.  Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis.

Authors:  Maria Escrivà; Sandra Peiró; Nicolás Herranz; Patricia Villagrasa; Natàlia Dave; Bàrbara Montserrat-Sentís; Stephen A Murray; Clara Francí; Thomas Gridley; Ismo Virtanen; Antonio García de Herreros
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

2.  Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.

Authors:  Amit Verma; Sushovan Guha; Huamin Wang; Jansina Y Fok; Dimpy Koul; James Abbruzzese; Kapil Mehta
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

3.  Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress.

Authors:  Gavin Y Oudit; Zamaneh Kassiri; Joyce Zhou; Qiao C Liu; Peter P Liu; Peter H Backx; Fayez Dawood; Michael A Crackower; James W Scholey; Josef M Penninger
Journal:  Cardiovasc Res       Date:  2008-02-15       Impact factor: 10.787

4.  CSIG inhibits PTEN translation in replicative senescence.

Authors:  Liwei Ma; Na Chang; Shuzhen Guo; Qian Li; Zongyu Zhang; Wengong Wang; Tanjun Tong
Journal:  Mol Cell Biol       Date:  2008-08-04       Impact factor: 4.272

5.  Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits.

Authors:  Amit K Mitra; Guanghong Jia; Deepak M Gangahar; Devendra K Agrawal
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

Review 6.  New insights into PTEN.

Authors:  Tanja Tamguney; David Stokoe
Journal:  J Cell Sci       Date:  2007-12-01       Impact factor: 5.285

7.  Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras.

Authors:  Krishna Murthi Vasudevan; Ravshan Burikhanov; Anindya Goswami; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

8.  RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells.

Authors:  Jimmy Y C Chow; Khai T Quach; Betty L Cabrera; Jennifer A Cabral; Stayce E Beck; John M Carethers
Journal:  Carcinogenesis       Date:  2007-07-17       Impact factor: 4.944

9.  Leptin-dependent phosphorylation of PTEN mediates actin restructuring and activation of ATP-sensitive K+ channels.

Authors:  Ke Ning; Lisa C Miller; Hilary A Laidlaw; Kenneth R Watterson; Jennifer Gallagher; Calum Sutherland; Michael L J Ashford
Journal:  J Biol Chem       Date:  2009-02-10       Impact factor: 5.157

10.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.

Authors:  M Frattini; P Saletti; E Romagnani; V Martin; F Molinari; M Ghisletta; A Camponovo; L L Etienne; F Cavalli; L Mazzucchelli
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

View more
  25 in total

Review 1.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

2.  Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer.

Authors:  S-J Kim; H-W Lee; J-H Baek; Y-H Cho; H G Kang; J S Jeong; J Song; H-S Park; K-H Chun
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

Review 3.  An update on PTEN modulators - a patent review.

Authors:  Chandra S Boosani; Palanikumar Gunasekar; Devendra K Agrawal
Journal:  Expert Opin Ther Pat       Date:  2019-09-23       Impact factor: 6.674

4.  Aberrant expression of TNRC6a and miR-21 during myocardial infarction.

Authors:  Liang Li; Qiang Chen; Chao Feng; Yongping Jin; Shudong Xia
Journal:  3 Biotech       Date:  2019-06-25       Impact factor: 2.406

Review 5.  Toward Systems Pathology for PTEN Diagnostics.

Authors:  Nahal Haddadi; Glena Travis; Najah T Nassif; Ann M Simpson; Deborah J Marsh
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

6.  The Paradox of Akt-mTOR Interactions.

Authors:  Lakshmipathi Vadlakonda; Abhinandita Dash; Mukesh Pasupuleti; Kotha Anil Kumar; Pallu Reddanna
Journal:  Front Oncol       Date:  2013-06-20       Impact factor: 6.244

7.  Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer.

Authors:  Iván Roa; Gonzalo de Toro; Fernanda Fernández; Anakaren Game; Sergio Muñoz; Xabier de Aretxabala; Milind Javle
Journal:  Diagn Pathol       Date:  2015-08-21       Impact factor: 2.644

8.  PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo.

Authors:  Kun-Chun Chiang; Huang-Yang Chen; Shu-Yuan Hsu; Jong-Hwei S Pang; Shang-Yu Wang; Jun-Te Hsu; Ta-Sen Yeh; Li-Wei Chen; Sheng-Fong Kuo; Chi-Chin Sun; Jim-Ming Lee; Chun-Nan Yeh; Horng-Heng Juang
Journal:  Drug Des Devel Ther       Date:  2015-08-13       Impact factor: 4.162

Review 9.  PTEN: Multiple Functions in Human Malignant Tumors.

Authors:  Michele Milella; Italia Falcone; Fabiana Conciatori; Ursula Cesta Incani; Anais Del Curatolo; Nicola Inzerilli; Carmen M A Nuzzo; Vanja Vaccaro; Sabrina Vari; Francesco Cognetti; Ludovica Ciuffreda
Journal:  Front Oncol       Date:  2015-02-16       Impact factor: 6.244

Review 10.  Genetic instability in the tumor microenvironment: a new look at an old neighbor.

Authors:  Antonio Palumbo; Nathalia de Oliveira Meireles Da Costa; Martin Hernan Bonamino; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.